Center-Authored Papers

Filters: Author is Coleman, Ilsa  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman I, Reed MJ, Nelson PS.  2018.  The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells.. Molecular cancer research : MCR. Abstract
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu SX, Brown M et al..  2011.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.. Cancer cell. 20(4):457-71. Abstract
Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S et al..  2013.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation.. PloS one. 8(5):e63563. Abstract
Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S.  2013.  AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.. Neoplasia (New York, N.Y.). 15(9):1009-17. Abstract
C
Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin VI.  2008.  A causal role for ERG in neoplastic transformation of prostate epithelium.. Proceedings of the National Academy of Sciences of the United States of America. 105(6):2105-10. Abstract
Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E et al..  2015.  Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.. PloS one. 10(6):e0130565. Abstract
Lam H-M, McMullin R, Nguyen H, Coleman I, Gormley M, Gulati R, Brown L, Holt S, Li W, Ricci DS et al..  2016.  Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B et al..  2013.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.. The Prostate. 73(9):932-40. Abstract
Roudier MP, Winters BR, Coleman I, Lam H-M, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B et al..  2016.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.. The Prostate. 76(9):810-22. Abstract
Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR, Ittmann M.  2017.  Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.. Oncotarget. 8(4):6179-6192. Abstract
Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS.  2009.  Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.. Cancer research. 69(5):1739-47. Abstract
D
Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, Lemeur N, Gentleman RC, True LD, Nelson PS, Lin DW.  2010.  Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(22):5414-23. Abstract
Gomez-Sarosi L, Sun Y, Coleman I, Bianchi-Frias D, Nelson PS.  2017.  DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes.. Molecular cancer research : MCR. Abstract
Huber RM, Lucas JM, Gomez-Sarosi LA, Coleman I, Zhao S, Coleman R, Nelson PS.  2015.  DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.. Oncotarget. 6(4):2134-47. Abstract
E
Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam H-M, Brown LG, Ketchanji M, Nghiem B, Lakely B et al..  2015.  Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.. Clinical & experimental metastasis. Abstract
Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD et al..  2015.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.. Cancer cell. 27(6):797-808. Abstract
Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ et al..  2011.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.. Proceedings of the National Academy of Sciences of the United States of America. 108(41):17087-92. Abstract
Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS et al..  2017.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.. Molecular cancer research : MCR. 15(5):521-531. Abstract
Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, Lin DW, Nelson PS, Ostrander EA, Feng Z et al..  2015.  Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.. The Prostate. Abstract
Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, Bjartell A.  2016.  Expression of STAT3 in Prostate Cancer Metastases.. European urology. Abstract
G
Rubicz R, Zhao S, Wright JL, Coleman I, Grasso C, Geybels MS, Leonardson A, Kolb S, April C, Bibikova M et al..  2017.  Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.. Molecular oncology. 11(2):140-150. Abstract
H
Koreckij TD, Trauger RJ, Montgomery RB, Pitts TEM, Coleman I, Nguyen H, Reading CL, Nelson PS, Vessella RL, Corey E.  2009.  HE3235 inhibits growth of castration-resistant prostate cancer.. Neoplasia (New York, N.Y.). 11(11):1216-25. Abstract
I
Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, Vasioukhin VI, Nelson P, Corey E, Üren A et al..  2017.  Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.. Anticancer research. 37(7):3385-3396. Abstract
N
Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M et al..  2017.  Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.. European urology. Abstract
P
Bluemn EG, Spencer SE, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C et al..  2013.  PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.. Molecular cancer research : MCR. 11(6):568-578. Abstract